Diabetes and the COVID-19 pandemic.
COVID-19
Coronavirus
Diabetes
Pandemic
Review
Journal
Diabetologia
ISSN: 1432-0428
Titre abrégé: Diabetologia
Pays: Germany
ID NLM: 0006777
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
21
06
2022
accepted:
30
09
2022
pubmed:
24
11
2022
medline:
5
1
2023
entrez:
23
11
2022
Statut:
ppublish
Résumé
Almost immediately after the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus emerged, it was evident that people with chronic diseases, including diabetes, were disproportionately affected, with an increased risk of hospitalisation and mortality. Over the ensuing 2 years, the indirect effects of the pandemic on healthcare delivery in the short term have become prominent, along with the lingering effects of the virus in those directly infected. In the wake of the pandemic and without any evidence from high quality studies, a number of national and international consensus recommendations were published, which were subsequently rapidly updated based on observational studies. There have been unprecedented disruptions from both direct and indirect impacts of coronavirus disease-2019 (COVID-19) in people with diabetes. In this review, we summarise the impact of acute COVID-19 in people with diabetes, discuss how the presentation and epidemiology during the pandemic, including presentation of diabetic ketoacidosis and new-onset diabetes, has changed, and we consider the wider impact of the pandemic on patients and healthcare service delivery, including some of the areas of uncertainty. Finally, we make recommendations on prioritising patients as we move into the recovery phase and also how we protect people with diabetes for the future, as COVID-19 is likely to become endemic.
Identifiants
pubmed: 36418578
doi: 10.1007/s00125-022-05833-z
pii: 10.1007/s00125-022-05833-z
pmc: PMC9685151
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
255-266Informations de copyright
© 2022. The Author(s).
Références
Zhou F, Yu T, Du R et al (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395(10229):1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3
doi: 10.1016/S0140-6736(20)30566-3
Williamson EJ, Walker AJ, Bhaskaran K et al (2020) Factors associated with COVID-19-related death using OpenSAFELY. Nature 584(7821):430–436. https://doi.org/10.1038/s41586-020-2521-4
doi: 10.1038/s41586-020-2521-4
Barron E, Bakhai C, Kar P et al (2020) Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol 8(10):813–822. https://doi.org/10.1016/s2213-8587(20)30272-2
doi: 10.1016/s2213-8587(20)30272-2
Holman N, Knighton P, Kar P et al (2020) Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol 8(10):823–833. https://doi.org/10.1016/S2213-8587(20)30271-0
doi: 10.1016/S2213-8587(20)30271-0
McGurnaghan SJ, Weir A, Bishop J et al (2021) Risks of and risk factors for COVID-19 disease in people with diabetes: a cohort study of the total population of Scotland. Lancet Diabetes Endocrinol 9(2):82–93. https://doi.org/10.1016/S2213-8587(20)30405-8
doi: 10.1016/S2213-8587(20)30405-8
Rawshani A, Kjolhede EA, Rawshani A et al (2021) Severe COVID-19 in people with type 1 and type 2 diabetes in Sweden: a nationwide retrospective cohort study. Lancet Reg Health Eur 4:100105. https://doi.org/10.1016/j.lanepe.2021.100105
doi: 10.1016/j.lanepe.2021.100105
Singh AK, Gillies CL, Singh R et al (2020) Prevalence of co-morbidities and their association with mortality in patients with COVID-19: a systematic review and meta-analysis. Diabetes Obes Metab 22(10):1915–1924. https://doi.org/10.1111/dom.14124
doi: 10.1111/dom.14124
Hartmann-Boyce J, Rees K, Perring JC et al (2021) Risks of and from SARS-CoV-2 infection and COVID-19 in people with diabetes: a systematic review of reviews. Diabetes Care 44(12):2790–2811. https://doi.org/10.2337/dc21-0930
doi: 10.2337/dc21-0930
Bornstein SR, Rubino F, Khunti K et al (2020) Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol 8(6):546–550. https://doi.org/10.1016/S2213-8587(20)30152-2
doi: 10.1016/S2213-8587(20)30152-2
Rayman G, Lumb A, Kennon B et al (2020) Guidelines for the management of diabetes services and patients during the COVID-19 pandemic. Diabet Med 37(7):1087–1089. https://doi.org/10.1111/dme.14316
doi: 10.1111/dme.14316
Hartmann-Boyce J, Morris E, Goyder C et al (2020) Diabetes and COVID-19: risks, management, and learnings from other national disasters. Diabetes Care 43(8):1695–1703. https://doi.org/10.2337/dc20-1192
doi: 10.2337/dc20-1192
Hanif S, Ali SN, Hassanein M, Khunti K, Hanif W (2020) Managing people with diabetes fasting for ramadan during the COVID-19 pandemic: a south Asian health foundation update. Diabetic Med J 37(7):1094–1102. https://doi.org/10.1111/dme.14312
doi: 10.1111/dme.14312
Steenblock C, Schwarz PEH, Ludwig B et al (2021) COVID-19 and metabolic disease: mechanisms and clinical management. Lancet Diabetes Endocrinol 9(11):786–798. https://doi.org/10.1016/S2213-8587(21)00244-8
doi: 10.1016/S2213-8587(21)00244-8
Yang Y, Cai Z, Zhang J (2021) Insulin treatment may increase adverse outcomes in patients with COVID-19 and diabetes: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 12:696087. https://doi.org/10.3389/fendo.2021.696087
doi: 10.3389/fendo.2021.696087
Lukito AA, Pranata R, Henrina J, Lim MA, Lawrensia S, Suastika K (2020) The effect of metformin consumption on mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis. Diabetes Metab Syndr 14(6):2177–2183. https://doi.org/10.1016/j.dsx.2020.11.006
doi: 10.1016/j.dsx.2020.11.006
Han T, Ma S, Sun C et al (2022) Association between anti-diabetic agents and clinical outcomes of COVID-19 in patients with diabetes: a systematic review and meta-analysis. Arch Med Res 53(2):186–195. https://doi.org/10.1016/j.arcmed.2021.08.002
doi: 10.1016/j.arcmed.2021.08.002
Hariyanto TI, Kurniawan A (2021) Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: a systematic review, meta-analysis, and meta-regression. J Diabetes Metab Disord 20(1):543–550. https://doi.org/10.1007/s40200-021-00777-4
doi: 10.1007/s40200-021-00777-4
Hariyanto TI, Intan D, Hananto JE, Putri C, Kurniawan A (2021) Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): a systematic review, meta-analysis, and meta-regression. Diabetes Res Clin Pract 179:109031. https://doi.org/10.1016/j.diabres.2021.109031
doi: 10.1016/j.diabres.2021.109031
Khunti K, Knighton P, Zaccardi F et al (2021) Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England. Lancet Diabetes Endocrinol 9(5):293–303. https://doi.org/10.1016/S2213-8587(21)00050-4
doi: 10.1016/S2213-8587(21)00050-4
Shrank WH, Patrick AR, Brookhart MA (2011) Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J Gen Intern Med 26(5):546–550. https://doi.org/10.1007/s11606-010-1609-1
doi: 10.1007/s11606-010-1609-1
Kosiborod MN, Esterline R, Furtado RHM et al (2021) Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 9(9):586–594. https://doi.org/10.1016/S2213-8587(21)00180-7
doi: 10.1016/S2213-8587(21)00180-7
Miller JL, Tada M, Goto M et al (2022) Prediction models for severe manifestations and mortality due to COVID-19: a systematic review. Acad Emerg Med 29(2):206–216. https://doi.org/10.1111/acem.14447
doi: 10.1111/acem.14447
Clift AK, Coupland CAC, Keogh RH et al (2020) Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. BMJ 371:m3731. https://doi.org/10.1136/bmj.m3731
doi: 10.1136/bmj.m3731
Knight SR, Ho A, Pius R et al (2020) Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: development and validation of the 4C mortality score. BMJ 370:m3339. https://doi.org/10.1136/bmj.m3339
doi: 10.1136/bmj.m3339
Hippisley-Cox J, Coupland CA, Mehta N et al (2021) Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study. BMJ 374:n2244. https://doi.org/10.1136/bmj.n2244
doi: 10.1136/bmj.n2244
Unsworth R, Wallace S, Oliver NS et al (2020) New-onset type 1 diabetes in children during COVID-19: multicenter regional findings in the U.K. Diabetes Care 43(11):e170–e171. https://doi.org/10.2337/dc20-1551
doi: 10.2337/dc20-1551
Chee YJ, Ng SJH, Yeoh E (2020) Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus. Diabetes Res Clin Pract 164:108166. https://doi.org/10.1016/j.diabres.2020.108166
doi: 10.1016/j.diabres.2020.108166
Li J, Wang X, Chen J, Zuo X, Zhang H, Deng A (2020) COVID-19 infection may cause ketosis and ketoacidosis. Diabetes Obes Metab 22(10):1935–1941. https://doi.org/10.1111/dom.14057
doi: 10.1111/dom.14057
Li H, Tian S, Chen T et al (2020) Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19. Diabetes Obes Metab 22(10):1897–1906. https://doi.org/10.1111/dom.14099
doi: 10.1111/dom.14099
Heaney AI, Griffin GD, Simon EL (2020) Newly diagnosed diabetes and diabetic ketoacidosis precipitated by COVID-19 infection. Am J Emerg Med 38(11):2491 e2493–2491 e2494. https://doi.org/10.1016/j.ajem.2020.05.114
doi: 10.1016/j.ajem.2020.05.114
Chan KH, Thimmareddygari D, Ramahi A, Atallah L, Baranetsky NG, Slim J (2020) Clinical characteristics and outcome in patients with combined diabetic ketoacidosis and hyperosmolar hyperglycemic state associated with COVID-19: a retrospective, hospital-based observational case series. Diabetes Res Clin Pract 166:108279. https://doi.org/10.1016/j.diabres.2020.108279
doi: 10.1016/j.diabres.2020.108279
Kim NY, Ha E, Moon JS, Lee YH, Choi EY (2020) Acute hyperglycemic crises with coronavirus disease-19: case reports. Diabetes Metab J 44(2):349–353. https://doi.org/10.4093/dmj.2020.0091
doi: 10.4093/dmj.2020.0091
Armeni E, Aziz U, Qamar S et al (2020) Protracted ketonaemia in hyperglycaemic emergencies in COVID-19: a retrospective case series. Lancet Diabetes Endocrinol 8(8):660–663. https://doi.org/10.1016/S2213-8587(20)30221-7
doi: 10.1016/S2213-8587(20)30221-7
Rubino F, Amiel SA, Zimmet P et al (2020) New-onset diabetes in Covid-19. N Engl J Med 383(8):789–790. https://doi.org/10.1056/NEJMc2018688
doi: 10.1056/NEJMc2018688
Muniangi-Muhitu H, Akalestou E, Salem V, Misra S, Oliver NS, Rutter GA (2020) Covid-19 and diabetes: a complex bidirectional relationship. Front Endocrinol 11:582936. https://doi.org/10.3389/fendo.2020.582936
doi: 10.3389/fendo.2020.582936
Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S (2020) COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol 8(9):782–792. https://doi.org/10.1016/S2213-8587(20)30238-2
doi: 10.1016/S2213-8587(20)30238-2
Kamrath C, Monkemoller K, Biester T et al (2020) Ketoacidosis in children and adolescents with newly diagnosed type 1 diabetes during the COVID-19 pandemic in Germany. JAMA 324(8):801–804. https://doi.org/10.1001/jama.2020.13445
doi: 10.1001/jama.2020.13445
Misra S, Barron E, Vamos E et al (2021) Temporal trends in emergency admissions for diabetic ketoacidosis in people with diabetes in England before and during the COVID-19 pandemic: a population-based study. Lancet Diabetes Endocrinol 9(10):671–680. https://doi.org/10.1016/S2213-8587(21)00208-4
doi: 10.1016/S2213-8587(21)00208-4
Lavik AR, Ebekozien O, Noor N et al (2022) Trends in type 1 diabetic ketoacidosis during COVID-19 surges at 7 US centers: highest burden on non-hispanic black patients. J Clin Endocrinol Metab 107(7):1948–1955. https://doi.org/10.1210/clinem/dgac158
doi: 10.1210/clinem/dgac158
Usher-Smith JA, Thompson M, Ercole A, Walter FM (2012) Variation between countries in the frequency of diabetic ketoacidosis at first presentation of type 1 diabetes in children: a systematic review. Diabetologia 55(11):2878–2894. https://doi.org/10.1007/s00125-012-2690-2
doi: 10.1007/s00125-012-2690-2
Garofolo M, Aragona M, Rodia C et al (2021) Glycaemic control during the lockdown for COVID-19 in adults with type 1 diabetes: a meta-analysis of observational studies. Diabetes Res Clin Pract 180:109066. https://doi.org/10.1016/j.diabres.2021.109066
doi: 10.1016/j.diabres.2021.109066
Ojo O, Wang XH, Ojo OO et al (2022) The effects of COVID-19 lockdown on glycaemic control and lipid profile in patients with type 2 diabetes: a systematic review and meta-analysis. Int J Environ Res Public Health 19(3):1095. https://doi.org/10.3390/ijerph19031095
doi: 10.3390/ijerph19031095
Dhatariya KK, Glaser NS, Codner E, Umpierrez GE (2020) Diabetic ketoacidosis. Nat Rev Dis Prim 6(1):40. https://doi.org/10.1038/s41572-020-0165-1
doi: 10.1038/s41572-020-0165-1
Misra S, Khozoee B, Huang J et al (2021) Comparison of diabetic ketoacidosis in adults during the SARS-CoV-2 outbreak and over the same time period for the preceding 3 years. Diabetes Care 44(2):e29–e31. https://doi.org/10.2337/dc20-2062
doi: 10.2337/dc20-2062
Kempegowda P, Melson E, Johnson A et al (2021) Effect of COVID-19 on the clinical course of diabetic ketoacidosis (DKA) in people with type 1 and type 2 diabetes. Endocr Connect 10(4):371–377. https://doi.org/10.1530/EC-20-0567
doi: 10.1530/EC-20-0567
Valabhji J, Barron E, Bradley D, Bakhai C, Khunti K, Jebb S (2021) Effect of the COVID-19 pandemic on body weight in people at high risk of type 2 diabetes referred to the English NHS diabetes prevention programme. Lancet Diabetes Endocrinol 9(10):649–651. https://doi.org/10.1016/S2213-8587(21)00218-7
doi: 10.1016/S2213-8587(21)00218-7
Zhong VW, Juhaeri J, Mayer-Davis EJ (2018) Trends in hospital admission for diabetic ketoacidosis in adults with type 1 and type 2 diabetes in England, 1998-2013: a retrospective cohort study. Diabetes Care 41(9):1870–1877. https://doi.org/10.2337/dc17-1583
doi: 10.2337/dc17-1583
Khunti K, Del Prato S, Mathieu C, Kahn SE, Gabbay RA, Buse JB (2021) COVID-19, hyperglycemia, and new-onset diabetes. Diabetes Care 44(12):2645–2655. https://doi.org/10.2337/dc21-1318
doi: 10.2337/dc21-1318
Xie Y, Al-Aly Z (2022) Risks and burdens of incident diabetes in long COVID: a cohort study. Lancet Diabetes Endocrinol. https://doi.org/10.1016/S2213-8587(22)00044-4
Shulman R, Cohen E, Stukel TA, Diong C, Guttmann A (2022) Examination of trends in diabetes incidence among children during the COVID-19 pandemic in Ontario, Canada, from March 2020 to September 2021. JAMA Netw Open 5(7):e2223394. https://doi.org/10.1001/jamanetworkopen.2022.23394
doi: 10.1001/jamanetworkopen.2022.23394
Accili D (2021) Can COVID-19 cause diabetes? Nat Metab 3(2):123–125. https://doi.org/10.1038/s42255-020-00339-7
doi: 10.1038/s42255-020-00339-7
Barrett CE, Koyama AK, Alvarez P et al (2022) Risk for newly diagnosed diabetes >30 days after SARS-CoV-2 infection among persons aged <18 years - United States, March 1, 2020-June 28, 2021. MMWR Morb Mortal Wkly Rep 71(2):59–65. https://doi.org/10.15585/mmwr.mm7102e2
doi: 10.15585/mmwr.mm7102e2
Kamrath C, Rosenbauer J, Eckert AJ et al (2022) Incidence of type 1 diabetes in children and adolescents during the COVID-19 pandemic in Germany: results from the DPV registry. Diabetes Care. https://doi.org/10.2337/dc21-0969
DiMeglio LA, Evans-Molina C, Oram RA (2018) Type 1 diabetes. Lancet 391(10138):2449–2462. https://doi.org/10.1016/S0140-6736(18)31320-5
doi: 10.1016/S0140-6736(18)31320-5
Quinn LM, Wong FS, Narendran P (2021) Environmental determinants of type 1 diabetes: from association to proving causality. Front Immunol 12:737964. https://doi.org/10.3389/fimmu.2021.737964
doi: 10.3389/fimmu.2021.737964
Muller JA, Gross R, Conzelmann C et al (2021) SARS-CoV-2 infects and replicates in cells of the human endocrine and exocrine pancreas. Nat Metab 3(2):149–165. https://doi.org/10.1038/s42255-021-00347-1
doi: 10.1038/s42255-021-00347-1
Liu P, Xu M, Lu L et al (2022) The changing pattern of common respiratory and enteric viruses among outpatient children in Shanghai, China: two years of the COVID-19 pandemic. J Med Virol 94(10):4696–4703. https://doi.org/10.1002/jmv.27896
doi: 10.1002/jmv.27896
Wan WY, Thoon KC, Loo LH et al (2021) Trends in respiratory virus infections during the COVID-19 pandemic in Singapore, 2020. JAMA Netw Open 4(6):e2115973. https://doi.org/10.1001/jamanetworkopen.2021.15973
doi: 10.1001/jamanetworkopen.2021.15973
Cromer SJ, Colling C, Schatoff D et al (2022) Newly diagnosed diabetes vs. pre-existing diabetes upon admission for COVID-19: Associated factors, short-term outcomes, and long-term glycemic phenotypes. J Diabetes Complicat 36(4):108145. https://doi.org/10.1016/j.jdiacomp.2022.108145
doi: 10.1016/j.jdiacomp.2022.108145
National Institute for Health and Care Excellence (2021) COVID-19 rapid guideline: managing COVID-19. Available from https://www.nice.org.uk/guidance/ng191 . Accesed on 14th April 2022
World Health Organization(WHO) (2021) Defintion of Covid 19. Available from https://www.who.int/emergencies/diseases/novel-coronavirus-2019 . Accessed on 14th April 2022
Routen A, O'Mahoney L, Ayoubkhani D et al (2022) Understanding and tracking the impact of long COVID in the United Kingdom. Nat Med 28(1):11–15. https://doi.org/10.1038/s41591-021-01591-4
doi: 10.1038/s41591-021-01591-4
Fernandez-de-Las-Penas C, Guijarro C, Torres-Macho J et al (2021) Diabetes and the risk of long-term post-COVID symptoms. Diabetes 70(12):2917–2921. https://doi.org/10.2337/db21-0329
doi: 10.2337/db21-0329
Xie Y, Xu E, Bowe B, Al-Aly Z (2022) Long-term cardiovascular outcomes of COVID-19. Nat Med 28(3):583–590. https://doi.org/10.1038/s41591-022-01689-3
doi: 10.1038/s41591-022-01689-3
Curtis HJ, MacKenna B, Croker R et al (2022) OpenSAFELY NHS service restoration observatory 1: primary care clinical activity in England during the first wave of COVID-19. Br J Gen Pract 72(714):e63–e74. https://doi.org/10.3399/BJGP.2021.0380
doi: 10.3399/BJGP.2021.0380
Carr MJ, Wright AK, Leelarathna L et al (2021) Impact of COVID-19 on diagnoses, monitoring, and mortality in people with type 2 diabetes in the UK. Lancet Diabetes Endocrinol 9(7):413–415. https://doi.org/10.1016/S2213-8587(21)00116-9
doi: 10.1016/S2213-8587(21)00116-9
Holman N, Knighton P, O'Keefe J et al (2021) Completion of annual diabetes care processes and mortality: a cohort study using the National Diabetes Audit for England and Wales. Diabetes Obes Metab 23(12):2728–2740. https://doi.org/10.1111/dom.14528
doi: 10.1111/dom.14528
McKay AJ, Gunn LH, Vamos EP et al (2021) Associations between attainment of incentivised primary care diabetes indicators and mortality in an English cohort. Diabetes Res Clin Pract 174:108746. https://doi.org/10.1016/j.diabres.2021.108746
doi: 10.1016/j.diabres.2021.108746
Carr MJ, Wright AK, Leelarathna L et al (2021) Impact of COVID-19 restrictions on diabetes health checks and prescribing for people with type 2 diabetes: a UK-wide cohort study involving 618 161 people in primary care. BMJ Qual Saf. https://doi.org/10.1136/bmjqs-2021-013613
Gunn LH, Vamos EP, Majeed A et al (2021) Associations between attainment of incentivized primary care indicators and incident lower limb amputation among those with type 2 diabetes: a population-based historical cohort study. BMJ Open Diabetes Res Care 9(1):e002069. https://doi.org/10.1136/bmjdrc-2020-002069
doi: 10.1136/bmjdrc-2020-002069
Valabhji J, Barron E, Vamos EP et al (2021) Temporal trends in lower-limb major and minor amputation and revascularization procedures in people with diabetes in england during the COVID-19 pandemic. Diabetes Care 44(6):e133–e135. https://doi.org/10.2337/dc20-2852
doi: 10.2337/dc20-2852
Valabhji J, Barron E, Gorton T et al (2022) Associations between reductions in routine care delivery and non-COVID-19-related mortality in people with diabetes in England during the COVID-19 pandemic: a population-based parallel cohort study. Online ahead of print. Lancet Diabetes Endocrinol. https://doi.org/10.1016/S2213-8587(22)00131-0
Burr O, Berry A, Joule N, Rayman G (2021) Inpatient diabetes care during the COVID-19 pandemic: a Diabetes UK rapid review of healthcare professionals' experiences using semi-structured interviews. Diabetic Med J 38(1):e14442. https://doi.org/10.1111/dme.14442
doi: 10.1111/dme.14442
Korytkowski M, Antinori-Lent K, Drincic A et al (2020) A pragmatic approach to inpatient diabetes management during the COVID-19 pandemic. J Clin Endocrinol Metab 105(9):dgaa342. https://doi.org/10.1210/clinem/dgaa342
doi: 10.1210/clinem/dgaa342
Niknam Z, Jafari A, Golchin A et al (2022) Potential therapeutic options for COVID-19: an update on current evidence. Eur J Med Res 27(1):6. https://doi.org/10.1186/s40001-021-00626-3
doi: 10.1186/s40001-021-00626-3
Sengul A, Ozer E, Salman S et al (2004) Lessons learnt from influences of the Marmara earthquake on glycemic control and quality of life in people with type 1 diabetes. Endocr J 51(4):407–414. https://doi.org/10.1507/endocrj.51.407
doi: 10.1507/endocrj.51.407
Fonseca VA, Smith H, Kuhadiya N et al (2009) Impact of a natural disaster on diabetes: exacerbation of disparities and long-term consequences. Diabetes Care 32(9):1632–1638. https://doi.org/10.2337/dc09-0670
doi: 10.2337/dc09-0670
Inui A, Kitaoka H, Majima M et al (1998) Effect of the Kobe earthquake on stress and glycemic control in patients with diabetes mellitus. Arch Intern Med 158(3):274–278. https://doi.org/10.1001/archinte.158.3.274
doi: 10.1001/archinte.158.3.274
Pibernik-Okanovic M, Roglic G, Prasek M, Metelko Z (1993) War-induced prolonged stress and metabolic control in type 2 diabetic patients. Psychol Med 23(3):645–651. https://doi.org/10.1017/s0033291700025423
doi: 10.1017/s0033291700025423
Chudasama YV, Gillies CL, Zaccardi F et al (2020) Impact of COVID-19 on routine care for chronic diseases: A global survey of views from healthcare professionals. Diabetes Metab Syndr 14(5):965–967. https://doi.org/10.1016/j.dsx.2020.06.042
doi: 10.1016/j.dsx.2020.06.042
Danne T, Limbert C, Puig Domingo M et al (2021) Telemonitoring, telemedicine and time in range during the pandemic: paradigm change for diabetes risk management in the post-COVID future. Diabetes Ther 12(9):2289–2310. https://doi.org/10.1007/s13300-021-01114-x
doi: 10.1007/s13300-021-01114-x
Crawford A, Serhal E (2020) Digital health equity and COVID-19: the innovation curve cannot reinforce the social gradient of health. J Med Internet Res 22(6):e19361. https://doi.org/10.2196/19361
doi: 10.2196/19361
Nagi D, Wilmott E, Owen K et al (2021) ABCD position statement on risk stratification of adult patients with diabetes during COVID-19 pandemic. Br J Diabetes 21(1):123–131. https://doi.org/10.15277/bjd.2021.282
doi: 10.15277/bjd.2021.282
Diggle J, Brown P (2020) How to undertake a remote diabetes review. Diabetes Primary Care 22(3):43
Profili F, Seghieri G, Francesconi P (2022) Effect of diabetes on short-term mortality and incidence of first hospitalizations for cardiovascular events after recovery from SARS-CoV-2 infection. Diabetes Res Clin Pract 187:109872. https://doi.org/10.1016/j.diabres.2022.109872
doi: 10.1016/j.diabres.2022.109872
Ayoubkhani D, Khunti K, Nafilyan V et al (2021) Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ 372:n693. https://doi.org/10.1136/bmj.n693
doi: 10.1136/bmj.n693
Marfella R, D'Onofrio N, Sardu C et al (2022) Does poor glycaemic control affect the immunogenicity of the COVID-19 vaccination in patients with type 2 diabetes: the CAVEAT study. Diabetes Obes Metab 24(1):160–165. https://doi.org/10.1111/dom.14547
doi: 10.1111/dom.14547
Sourij C, Tripolt NJ, Aziz F et al (2022) Humoral immune response to COVID-19 vaccination in diabetes is age-dependent but independent of type of diabetes and glycaemic control: the prospective COVAC-DM cohort study. Diabetes Obes Metab 24(5):849–858. https://doi.org/10.1111/dom.14643
doi: 10.1111/dom.14643
Marfella R, Sardu C, D'Onofrio N et al (2022) Glycaemic control is associated with SARS-CoV-2 breakthrough infections in vaccinated patients with type 2 diabetes. Nat Commun 13(1):2318. https://doi.org/10.1038/s41467-022-30068-2
doi: 10.1038/s41467-022-30068-2